Zynga (NASDAQ: ZNGA), Moderna (NASDAQ: mRNA), and Tilray (NASDAQ: TLRY) are three top growth stocks that have increased 64%, 658% and 299%, respectively, in the past year alone. Go back to the top of the S&P 500s by 19% over the same period, hands down.
With this bull market still in its infancy, many winners keep winning and many losers keep losing. Let’s take a look at why now is a good time to buy these three stocks – and why their momentum may just be starting.
ZNGA Total Yield Level given by YCharts
1. Zynga
Last year, video game developer Zynga saw its revenue hit a record high of $ 1.97 billion, an annual increase of 49% over 2019. At the same time, its flow of Operating cash flow improved 63% to $ 429 million. Highlights of the year include the launch of Harry Potter: puzzles and spells, which received the 2020 Google Play award for best casual game. It also has a rating of 4.7 on the Google Play and Android platforms.
Image source: Getty Images.
The company also acquired Peak (the maker of Cartoon explosion and Toy explosion) as good as Rollic, which has three of the 50 most downloaded games in the United States for iPhone. An estimated 36 million active users play any of Zynga’s titles every day.
This year, Zynga plans to further increase sales to $ 2.6 billion. Despite a remarkable projection for year-over-year revenue growth of 32%, the stock only trades 5 times sales. For investors looking for quality technological actions at the right price, Zynga is your best bet.
2. Modern
Regulatory authorities around the world are moving at a record pace to phase out Moderna’s mRNA-1273 coronavirus vaccine in hopes of ending the pandemic. More than 115 million doses of the vaccine have been ordered in the past 30 days, and Moderna plans to produce up to 1 billion doses of mRNA-1273 this year, with that number rising to 1.2 billion by the end. from 2022.
Based on advance purchase agreements, the company already has nearly $ 12 billion in revenue in the bag for 2021. Additionally, the vaccine appears to retain its protection against the British and South African mutant strains of SARS- CoV-2, as shown in a study. It previously showed 94% efficacy against the original strains of the coronavirus.
Right now, you can buy Moderna shares for just 7 times the income, which is still cheaper than the biotech industry average, which is 8 times the sale price. And developing coronavirus vaccines isn’t the company’s only goal – Moderna could potentially generate up to $ 5 billion in maximum annual sales if it manages to bring its CMV vaccine to market. In addition, it has nine viral vaccines in its pipeline, as well as 13 therapeutic candidates.
3. Tilray
Canadian pot producers Aphria (NASDAQ: APHA) and Tilray are set to merge to become the world’s largest cannabis producer, with combined revenues totaling C $ 874 million in the past 12 months. After the deal closes, the combined company is said to have a near-full pipeline of marijuana products, including flowers, pre-rolls, medical cannabis, oils, vapes, capsules, edibles, and cannabis. beverages – the only category missing is pharmaceuticals.
Together, the two giants rank number one in the Canadian marijuana market, with a 17.3% stake. Aphria has strong sales of medical marijuana from Germany, as well as beverage revenue from its US subsidiary. Meanwhile, Tilray also has its own line of CBD operations in the south.
In its latest earnings report (completed November 30), Aphria increased sales from C $ 120.6 million in the last quarter of last year to C $ 160.5 million. It is now breaking even, compared to a loss of C $ 48.8 million in the second quarter of 2020. Compared to the previous quarter, Aphria increased the amount of dried cannabis it sold by approximately 5,000 kilograms to 22,347 kg.
Given the strong recovery in the Canadian legal weed market, Tilray’s stock is still up at 19 times forward sales. And the real jewel in the crown – its potential to enter the US THC market in the face of the federal threat decriminalization – is yet to come.
Here’s the marijuana stock you’ve been waiting for
A little-known Canadian company has just unlocked what some experts believe is the key to profiting from the upcoming marijuana boom.
And make no mistake, it does happen.
Cannabis legalization is sweeping across North America – 15 states plus Washington, DC, have all legalized recreational marijuana in recent years, and full legalization arrived in Canada in October 2018.
And an under the radar Canadian business is about to explode because of this upcoming marijuana revolution.
Because a game-changing deal has just been struck between the Government of Ontario and this mighty company … and you must hear this story today if you’ve even considered investing in pot stocks. .
Just click here to get the full story now.
Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares and recommends Zynga. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
